Shandong Wohua Pharmaceutical Co (SZSE:002107) Net Income From Continuing Operations : ¥33.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Shandong Wohua Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Shandong Wohua Pharmaceutical Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥8.8 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥33.2 Mil.

Shandong Wohua Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Shandong Wohua Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Wohua Pharmaceutical Co Net Income From Continuing Operations Chart

Shandong Wohua Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

97.24

186.33

161.32

89.89

46.63

Shandong Wohua Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															22.23	7.33	16.87	0.19	8.76

Shandong Wohua Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥33.2 Mil.

Shandong Wohua Pharmaceutical Co (SZSE:002107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

Fushou East Street, Chuangye Building, 2F, New and High-Tech Industrial Development Zone, Huaifang, Shandong, CHN, 261011

Website

http://www.wohua.cn

Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.

Executives

Zhao Jun	Director
Liu Wen Yi	Supervisors
Zhang Fa Zhong	Supervisors
Zhang Ge	Director
Ma Xing Chen	Supervisors
Tian Kai Ji	Directors, executives
Kong Xian Jun	Supervisors

Shandong Wohua Pharmaceutical Co (SZSE:002107) Headlines

No Headlines